Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2022 | Insights from cenobamate studies

Bernhard Steinhoff, MD, PhD, Kork Epilepsy Center, Kehl-Kork, Germany, discusses what is currently known about the treatment of epilepsy with cenobamate and highlights what aspects should be further characterized. Clinical trials and subanalyses have shown that cenobamate is an effective drug and a good therapeutic choice for adults with epilepsy with focal onset seizures, including patients with more severe cases of epilepsy. Cenobamate is a drug with a high interaction profile; therefore, drug-drug interactions should be carefully investigated. This interview took place at the 2022 Congress of the European Academy of Neurology (EAN) in Vienna, Austria.